TY  - JOUR
TI  - Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?
AB  - Objectives: Pegylated-interferon (Peg-IFN) alpha 2a/2b andnucleoside and/or nucleotide analogues (NAs) are currently theonly two treatment approaches approved for the chronic hepatitisB (CHB). To date, few studies have compared Peg-IFN with NAsin the treatment of CHB. We aimed in this study to evaluate theeffectiveness of Peg-IFN and potent NAs (entecavir and tenofovirdisoproxil) and to compare cumulative virological and serologicalresponses in Turkish CHB patients treated between 2006 and 2016.Materials and Methods: In this observational retrospective study,we divided a total of 331 patients, who were diagnosed with CHB,into 3 groups: Peg-IFN treatment group (n=62), entecavir treatmentgroup (n=131) and tenofovir disoproxil treatment group (n=138).Results: Virologic response rate in the Peg-IFN treatment group(90%) at 12 months was higher than in the NAs treatment groups(80% for entecavir and 76% for tenofovir disoproxil) (p<0.05).Sustained virologic response (SVR) rate at 24 months was 61%in the Peg-IFN group (p<0.001). The rate of hepatitis B e antigenseroconversion was significantly higher in the Peg-IFN group (25%)than in the NAs groups (16% for entecavir, 13% for tenofovirdisoproxil). Hepatitis B surface antigen (HBsAg) seroconversion ratewas also higher in the Peg-IFN than in the NAs treatment groups(7.9% vs. 0.9% and 0%, respectively) (p<0.001). After HBsAgseroconversion, the titers of anti-HBs were retained for over sixmonths.Conclusion: Peg-IFN treatment was found to be effective with highSVR and hepatitis B e antigen and HBsAg seroconversion rates thanNAs treatment in long-term follow-up of patients with CHB. Peg-IFNappears to be the first-choice treatment approach in patients withCHB until a new era in which hepatitis B is cured.
AU  - SARIGÜL YILDIRIM, Figen
AU  - SAYAN, Murat
AU  - ÜSER, Ülkü
AU  - ÖZTOPRAK ÇUVALCI, NEFİSE
DO  - 10.4274/vhd.2018.0006
PY  - 2018
JO  - Viral Hepatitis Journal
VL  - 24
IS  - 3
SN  - 2147-2939
SP  - 90
EP  - 95
DB  - TRDizin
UR  - http://search/yayin/detay/310876
ER  -